Table 1 Characteristics of persons with HIV on ART at enrolment into HONOR, by HIV plasma viral load, Liberia

From: HIV-1 suppression and rare dolutegravir resistance in antiretroviral-experienced people with HIV in Liberia

 

HIV plasma viral load (copies/mL)

 
 

<40

40-999

≥1000

Totala

Characteristic

N = 970

N = 141

N = 90

N = 1201

Age, years, median (IQR)

43 (35–51)

40 (34–47)

38 (30–44)

42 (35–50)

Age groups

 <15

26 (70%)

6 (16%)

5 (14%)

37 (3.1%)

 15–24

35 (65%)

9 (17%)

10 (19%)

54 (4.5%)

 25–49

630 (79%)

98 (12%)

65 (8.2%)

793 (66%)

 ≥50

279 (88%)

28 (8.8%)

10 (3.2%)

317 (26%)

Sex assigned at birth

 Male

261 (78%)

49 (15%)

25 (7.5%)

335 (28%)

 Female

709 (82%)

92 (11%)

65 (7.5%)

866 (72%)

Level of educationb

 None

195 (81%)

26 (11%)

19 (7.9%)

240 (20%)

 Primary-high school

586 (81%)

82 (11%)

55 (7.6%)

723 (61%)

 Vocational-University

177 (80%)

30 (14%)

13 (5.9%)

220 (19%)

BMI, kg/m2, median (IQR)b

24 (21–28)

23 (21–28)

23 (20–26)

23 (21–28)

Hemoglobin (g/dL)b,c

 ≥11

816 (84%)

100 (10%)

52 (5.4%)

968 (81%)

 <11

149 (66%)

40 (18%)

38 (17%)

227 (19%)

D-dimer (mg/dL)b

 Normal (≤0·5 µg/mL)

674 (85%)

75 (9.4%)

45 (5.7%)

794 (67%)

 Elevated (>0·5 µg/mL)

282 (73%)

62 (16%)

41 (11%)

385 (33%)

Years since HIV diagnosis, median (IQR)b

6.9 (2.8–11)

3.7 (1.4–8.3)

6.2 (1.9–11)

6.6 (2.6–11)

Years since starting ART, median (IQR)

6.6 (2.4–11)

3.0 (1.0–8.1)

6.0 (1.8–9.9)

6.1 (2.1–11)

pVL log10 (copies/mL), median (IQR)

1.3 (1.3–1.3)

2.0 (1.8–2.4)

4·2 (3.4–4.9)

1.3 (1.3–2.1)

CD4 count (cells/µL), median (IQR)

604 (411–818)

430 (280–644)

313 (192–514)

558 (362–779)

CD4 count (cells/µL)b

 ≥500

579 (89%)

49 (7.5%)

22 (3.4%)

650 (58%)

 200–499

271 (72%)

65 (17%)

39 (10%)

375 (34%)

 <200

52 (56%)

18 (19%)

23 (25%)

93 (8%)

ART regimen at enrollmentd

 Efavirenz (EFV)/Nevirapine (NVP)

216 (77%)

26 (9.3%)

39 (14%)

281 (23%)

 Dolutegravir (DTG)-based regimen

739 (83%)

108 (12%)

47 (5.3%)

894 (74%)

  Switched from NNRTI- to DTG-based regimene

361 (84%)

49 (11%)

22 (5.1%)

432 (48%)

  Started ART on DTG-based regimen

368 (82%)

57 (13%)

24 (5.3%)

449 (50%)

 Lopinavir/ritonavir (LPV/r)/Nelfinavir (NFV)f

15 (58%)

7 (27%)

4 (15%)

26 (2.2%)

Past ARV history

 Zidovudine (AZT)

204 (84%)

20 (8.2%)

19 (7.8%)

243 (20%)

 EFV/NVP

504 (51%)

58 (9.7%)

36 (6.0%)

598 (50%)

 DTG

0

0

1 (100%)

1 (0.1%)

 LPV/r/NFV

16 (70%)

4 (17%)

3 (13%)

23 (1.9%)

  1. 3TC lamivudine, ABC abacavir, ART antiretroviral therapy, ARV antiretroviral, BMI body mass index, IQR interquartile range, NNRTI non-nucleoside reverse transcriptase inhibitor, pVL plasma viral load, TDF tenofovir.
  2. aValues in this column are denominators for row statistics.
  3. bMissing data: Education (N = 18 infants), BMI (N = 4), Hemoglobin (N = 6), D-dimer (N = 22), Years since HIV diagnosis (N = 12), and CD4 count (N = 83).
  4. cNormal hemoglobin (g/dL) for: female: ≥12 (pregnant: ≥11), male: ≥13, and children (0·5–4·9 years: ≥11, 5–11: ≥12, 12–14 years: ≥12).
  5. dCombined with 3TC+TDF (1167/1201 [97%]), 3TC+AZT (15/1201 [1.2%]), and 3TC+ABC (16/1201 [1.3%]).
  6. eThe row total excludes 13 individuals (pVL<40 = 10, pVL 40-999 = 2, and pVL >= 1000 = 1) with past exposure to LPV/r-based regimens.
  7. fIncludes 3 participants on NFV-based ART.
Back to article page